Investor News

Medistim ASA invites you to the presentation of its financial results for the third quarter 2024.

After years of preparation, Medistim has successfully obtained its first CE certificates under the latest EU Medical Device Regulation (EU MDR 2017/745).

Total sales ended at MNOK 144.9, 5.5% above second quarter last year (MNOK 137.4). This is a new record for a quarter. For the first half, sales ended at MNOK 278.7, 4.5% above last year (MNOK 266.6). Currency neutral sales of own products was up 1.7% for the quarter and 1.5% for the first half. Recurring sales remain high at 73% (72%) for the quarter and 74% (71%) for the first half, underscoring the sustained momentum in utilization among our customers.

Sales ended at MNOK 133.8, 3.5% above the first quarter last year (MNOK 129.3). Currency neutral sales of own products was down 1%. Recurring sales remain high at 75% or MNOK 83.5 (68% or MNOK 73.8) for the quarter.

Currency neutral sales of own products was down 17.4 % for the quarter and down 5.1 % for the year. Download the full report and presentation, and watch the video recording from the webinar below.…

This move is part of the company's ongoing commitment to providing exceptional service to customers as well as fulfilling the company’s global growth strategy. The company is well positioned to continue its growth by further…